Re: drugn product degradent

[Malcolm Ross <generapharm@gmail.com> (by way of John Dolman<info@the-dolman-consultancy.com>)]

A different synthetic route can certainly lead to 
different degradation. I had an example where one 
process involved catalysis and the other did not. 
The two API's both based specification but one 
degraded quite rapidly whereas the other was stable.

Malcolm Ross
Generapharm



-- 
Dr. Malcolm Ross
Generapharm-Training and Consultancy
Rümelinbachweg 16
Basel 4054
Switzerland

The GMP Discussion Group is sponsored by gmp review - see
http://www.pharmweb.net/gmp.html